NextPlat (NXPL) Cost of Revenue (2015 - 2026)
NextPlat's (NXPL) quarterly Cost of Revenue came in at $7.2 million in Q2 2026, down 30.61% year-over-year from $10.4 million in Q2 2025, and up 11.55% quarter-over-quarter from $6.4 million in Q1 2026.
Analysis
NextPlat (NXPL) Cost of Revenue (2015 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Cost of Revenue for 12 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cost of Revenue fell 30.61% year-over-year to $7.2 million in Q2 2026; TTM through Jun 2026 was $35.6 million, a 23.76% decrease from a year earlier, with the FY2025 full-year figure at $43.4 million, down 11.53% from the prior year.
- Cost of Revenue was $7.2 million for Q2 2026 at NextPlat, up from $6.4 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $13.5 million in Q4 2024 and troughed at $2.0 million in Q3 2022.
- A 5-year average of $7.9 million and a median of $10.5 million in 2023 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue jumped 460.09% in 2024 and slumped 41.76% in 2026, its largest moves.
- Over 5 years, Cost of Revenue stood at $2.2 million in 2022, then soared by 419.66% to $11.4 million in 2023, then climbed by 18.76% to $13.5 million in 2024, then declined by 18.73% to $11.0 million in 2025, then slumped by 34.51% to $7.2 million in 2026.
- The last three Cost of Revenue figures came in at $7.2 million (Q2 2026), $6.4 million (Q1 2026), and $11.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 1.99 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 2.30 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 455.94 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 461.69 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 753.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 100.16 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 52.20 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 90.43 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 721,000.00 |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.19 Mn |
| Mar 31, 2026 | 6.44 Mn |
| Dec 31, 2025 | 10.98 Mn |
| Sep 30, 2025 | 11.02 Mn |
| Jun 30, 2025 | 10.36 Mn |
| Mar 31, 2025 | 11.06 Mn |
| Dec 31, 2024 | 13.50 Mn |
| Sep 30, 2024 | 11.81 Mn |
| Jun 30, 2024 | 11.13 Mn |
| Mar 31, 2024 | 12.63 Mn |
| Dec 31, 2023 | 11.37 Mn |
| Sep 30, 2023 | 10.71 Mn |
| Jun 30, 2023 | 2.11 Mn |
| Mar 31, 2023 | 2.26 Mn |
| Dec 31, 2022 | 2.19 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 2.30 Mn |
| Mar 31, 2022 | 2.78 Mn |
| Dec 31, 2021 | 1.68 Mn |
| Sep 30, 2021 | 1.76 Mn |